Printer Friendly

Ardelyx Study of Tenapanor for IBS-C Hits Demonstrates Ability to Normalize Bowel Function.

M2 PHARMA-October 12, 2017-Ardelyx Study of Tenapanor for IBS-C Hits Demonstrates Ability to Normalize Bowel Function

(C)2017 M2 COMMUNICATIONS

- Fremont, California-based cardio, renal, and gastrointestinal disease therapeutics developer Ardelyx, Inc. (NASDAQ: ARDX) has reported positive results from T3MPO-2, its second Phase 3 study of tenapanor for irritable bowel syndrome with constipation (IBS-C), the company said.

The study hit statistical significance for the primary endpoint and all secondary endpoints evaluated for the topline results and demonstrated the ability to normalize bowel movements.

The primary endpoint, the combined responder rate for six of 12 weeks, showed that a greater proportion of tenapanor-treated patients compared to placebo-treated patients (36.5% vs. 23.7%, p

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Oct 12, 2017
Words:123
Previous Article:BioPharmX and Wellman Center for Photomedicine Researchers Develop Optical Imaging Technique to Visualize Drug Delivery.
Next Article:AbbVie to Present Mavyret (glecaprevir/pibrentasvir) Data.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters